SG11201809064QA - Chimeric neurotoxins - Google Patents
Chimeric neurotoxinsInfo
- Publication number
- SG11201809064QA SG11201809064QA SG11201809064QA SG11201809064QA SG11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA SG 11201809064Q A SG11201809064Q A SG 11201809064QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- english
- unless
- indicated
- Prior art date
Links
- 239000002581 neurotoxin Substances 0.000 title abstract 3
- 231100000618 neurotoxin Toxicity 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1607901.4A GB201607901D0 (en) | 2016-05-05 | 2016-05-05 | Chimeric neurotoxins |
PCT/EP2017/060821 WO2017191315A1 (fr) | 2016-05-05 | 2017-05-05 | Neurotoxines chimères |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809064QA true SG11201809064QA (en) | 2018-11-29 |
Family
ID=56297235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809064QA SG11201809064QA (en) | 2016-05-05 | 2017-05-05 | Chimeric neurotoxins |
Country Status (23)
Country | Link |
---|---|
US (2) | US11434265B2 (fr) |
EP (2) | EP3889168A1 (fr) |
JP (3) | JP7421862B2 (fr) |
KR (2) | KR102643970B1 (fr) |
CN (2) | CN116333158A (fr) |
AR (1) | AR108689A1 (fr) |
AU (3) | AU2017260389B2 (fr) |
BR (1) | BR112018072587A2 (fr) |
CA (1) | CA3020640A1 (fr) |
DK (1) | DK3452071T3 (fr) |
EA (1) | EA201892386A1 (fr) |
ES (1) | ES2866899T3 (fr) |
GB (1) | GB201607901D0 (fr) |
HU (1) | HUE054856T2 (fr) |
IL (1) | IL262575B (fr) |
MX (1) | MX2018013141A (fr) |
PL (1) | PL3452071T3 (fr) |
PT (1) | PT3452071T (fr) |
SA (1) | SA518400335B1 (fr) |
SG (1) | SG11201809064QA (fr) |
TW (2) | TWI751157B (fr) |
UA (1) | UA126563C2 (fr) |
WO (1) | WO2017191315A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3372239B1 (fr) | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Neurotoxine botulique ingéniérisée |
CN104870468B (zh) | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
EP3274364B1 (fr) * | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Neurotoxine botulique ingéniérisée |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
KR20190025906A (ko) * | 2016-06-08 | 2019-03-12 | 칠드런'즈 메디컬 센터 코포레이션 | 조작된 보툴리눔 신경독소 |
US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
TWI810228B (zh) | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
US20210024747A1 (en) * | 2018-04-06 | 2021-01-28 | Dupont Polymers, Inc. | Additive manufacturing compositions |
US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
EP3753568A1 (fr) | 2019-06-21 | 2020-12-23 | Fastox Pharma SA | Composition modulant l'effet de la neurotoxine botulique |
GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
GB202001353D0 (en) | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
BR112022018456A2 (pt) | 2020-03-16 | 2022-11-01 | Ipsen Biopharm Ltd | Tratamento de espasticidade de membro |
GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
GB202104294D0 (en) * | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
WO2022208091A1 (fr) | 2021-03-30 | 2022-10-06 | Ipsen Biopharm Limited | Traitement de troubles inflammatoires et de la douleur |
CA3211472A1 (fr) | 2021-03-30 | 2022-10-06 | Mikhail KALINICHEV | Neurotoxines clostridiales catalytiquement inactives pour le traitement de la douleur et de troubles inflammatoires |
CA3231083A1 (fr) | 2021-09-16 | 2023-03-23 | Nicolae GRIGORE | Bont/a modifiee destinee a etre utilisee dans le traitement de la dystonie cervicale |
GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
CA3228712A1 (fr) | 2021-09-23 | 2023-03-30 | Nicolae GRIGORE | Bont/a modifiee destinee a etre utilisee dans le traitement d'un trouble affectant un muscle de la paupiere d'un sujet |
GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
CA3234608A1 (fr) | 2021-11-22 | 2023-05-25 | Ipsen Biopharm Limited | Traitement de la douleur |
GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69435253D1 (de) | 1993-06-10 | 2009-12-31 | Allergan Inc | Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US6545126B1 (en) * | 1999-03-18 | 2003-04-08 | Wisconsin Alumni Research Foundation | Chimeric toxins |
US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
KR20050061541A (ko) | 2002-10-15 | 2005-06-22 | 알러간, 인코포레이티드 | 보툴리눔 독소 치과 치료 및 시술 |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
CN102131823A (zh) * | 2008-08-29 | 2011-07-20 | 德国麦氏大药厂 | 具有改变的持久性的梭状芽孢杆菌神经毒素 |
GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
AU2010236613B2 (en) | 2009-04-14 | 2016-07-07 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
JP6148979B2 (ja) * | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドAllergan,Incorporated | 分解性クロストリジウム毒素 |
US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
EP2798077A2 (fr) * | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Dosage cellulaire extrêmement sensible pour détecter la présence d'une neurotoxine active botulique de sérotype a |
EP3372239B1 (fr) * | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Neurotoxine botulique ingéniérisée |
CN104870468B (zh) * | 2012-11-21 | 2020-11-10 | 益普生生物创新有限公司 | 用于制备经蛋白水解处理的多肽的方法 |
GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
US9216210B2 (en) * | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
EP3822286A1 (fr) * | 2015-01-09 | 2021-05-19 | Ipsen Bioinnovation Limited | Neurotoxines cationiques |
EP3274364B1 (fr) * | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Neurotoxine botulique ingéniérisée |
US11753633B2 (en) * | 2015-08-27 | 2023-09-12 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
KR20190025906A (ko) * | 2016-06-08 | 2019-03-12 | 칠드런'즈 메디컬 센터 코포레이션 | 조작된 보툴리눔 신경독소 |
CA3030155A1 (fr) * | 2016-07-08 | 2018-01-11 | Children's Medical Center Corporation | Nouvelle neurotoxine botulique et ses derives |
US11117935B2 (en) * | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
CN110430892A (zh) * | 2017-03-24 | 2019-11-08 | 梅尔兹制药公司 | 肉毒神经毒素在治疗流涎中的改进的用途 |
US10329543B2 (en) * | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
WO2019152380A1 (fr) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production de neurotoxines de botulinum à l'aide de systèmes bacillus |
BR112020021804A2 (pt) * | 2018-04-27 | 2021-02-23 | Krystal Biotech, Inc. | genoma de herpes vírus recombinante, vírus herpes, composição, uso do vírus herpes, métodos para intensificar, aumentar, ampliar e/ou suplementar os níveis de uma ou mais proteínas da matriz extracelular dérmica, de uma ou mais proteínas de colágeno, o tecido mole de um sujeito, para melhorar a condição, qualidade e/ou aparência da pele, para reduzir o aparecimento de uma ou mais depressões superficiais na pele, para aumentar e/ou melhorar pelo menos um de textura, suavidade, elasticidade ou tensão da pele e para diminuir um ou mais sinais dermatológicos de envelhecimento |
-
2016
- 2016-05-05 GB GBGB1607901.4A patent/GB201607901D0/en not_active Ceased
-
2017
- 2017-05-05 HU HUE17724335A patent/HUE054856T2/hu unknown
- 2017-05-05 CA CA3020640A patent/CA3020640A1/fr active Pending
- 2017-05-05 BR BR112018072587-0A patent/BR112018072587A2/pt unknown
- 2017-05-05 KR KR1020187034781A patent/KR102643970B1/ko active IP Right Grant
- 2017-05-05 AR ARP170101177A patent/AR108689A1/es unknown
- 2017-05-05 MX MX2018013141A patent/MX2018013141A/es unknown
- 2017-05-05 TW TW106114984A patent/TWI751157B/zh active
- 2017-05-05 CN CN202210871196.6A patent/CN116333158A/zh active Pending
- 2017-05-05 ES ES17724335T patent/ES2866899T3/es active Active
- 2017-05-05 SG SG11201809064QA patent/SG11201809064QA/en unknown
- 2017-05-05 UA UAA201812004A patent/UA126563C2/uk unknown
- 2017-05-05 KR KR1020247007005A patent/KR20240033165A/ko active Application Filing
- 2017-05-05 EA EA201892386A patent/EA201892386A1/ru unknown
- 2017-05-05 TW TW111106023A patent/TWI832162B/zh active
- 2017-05-05 EP EP21161122.3A patent/EP3889168A1/fr active Pending
- 2017-05-05 DK DK17724335.9T patent/DK3452071T3/da active
- 2017-05-05 AU AU2017260389A patent/AU2017260389B2/en active Active
- 2017-05-05 CN CN201780026413.9A patent/CN109069576B/zh active Active
- 2017-05-05 PL PL17724335T patent/PL3452071T3/pl unknown
- 2017-05-05 JP JP2018558218A patent/JP7421862B2/ja active Active
- 2017-05-05 WO PCT/EP2017/060821 patent/WO2017191315A1/fr active Application Filing
- 2017-05-05 PT PT177243359T patent/PT3452071T/pt unknown
- 2017-05-05 EP EP17724335.9A patent/EP3452071B1/fr active Active
- 2017-05-05 US US16/094,254 patent/US11434265B2/en active Active
-
2018
- 2018-10-24 IL IL262575A patent/IL262575B/en unknown
- 2018-10-29 SA SA518400335A patent/SA518400335B1/ar unknown
-
2021
- 2021-11-11 AU AU2021266312A patent/AU2021266312B2/en active Active
-
2022
- 2022-04-27 JP JP2022073033A patent/JP2022105100A/ja active Pending
- 2022-07-12 US US17/811,958 patent/US20230025090A1/en active Pending
-
2023
- 2023-10-18 JP JP2023179513A patent/JP2024010008A/ja active Pending
-
2024
- 2024-04-10 AU AU2024202302A patent/AU2024202302A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809064QA (en) | Chimeric neurotoxins | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201909303TA (en) | Point of delivery cold slurry generation | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201808306PA (en) | Treatment of cancer with tg02 | |
SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201908275XA (en) | Peptides and methods for the treatment of diabetes | |
SG11201807062RA (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
SG11201906464UA (en) | Csf1r-based chimeric proteins | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same |